1 to 10 of 610 trials

• Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes

  conditions:	Hypereosinophilic Syndrome ; Chronic Eosinophilic Leukemia ; Chronic Idiopathic Hypereosinophilia
  interventions:	Imatinib
  last updated:	2008 Nov 7
  status:	completed
  sponsor:	Northern Italy Leukemia Group

   

• Efficacy and Safety of Imatinib in Chordoma

  conditions:	Chordoma
  interventions:	imatinib
  last updated:	2009 Sep 22
  status:	completed
  sponsor:	Novartis Pharmaceuticals

   

• Imatinib Mesylate in Treating Patients With Gliomas

  conditions:	Brain and Central Nervous System Tumors
  interventions:	imatinib mesylate
  last updated:	2008 Nov 22
  status:	active, not recruiting
  sponsor:	European Organization for Research and Treatment of Cancer

   

• Imatinib Mesylate in Treating Patients With Myelofibrosis

  conditions:	Chronic Myeloproliferative Disorders ; Leukemia
  interventions:	imatinib mesylate
  last updated:	2008 Jul 23
  status:	active, not recruiting
  sponsor:	University of Chicago

   

• Imatinib Mesylate in Treating Patients With Recurrent Meningioma

  conditions:	Brain and Central Nervous System Tumors
  interventions:	imatinib mesylate
  last updated:	2009 Mar 24
  status:	completed
  sponsor:	North American Brain Tumor Consortium

   

• Imatinib Mesylate in Treating Patients With Myelofibrosis

  conditions:	Chronic Myeloproliferative Disorders
  interventions:	imatinib mesylate
  last updated:	2009 Apr 4
  status:	active, not recruiting
  sponsor:	OHSU Knight Cancer Institute

   

• Effects of Imatinib Mesylate in Polycythemia Vera

  conditions:	Polycythemia Vera
  interventions:	Imatinib Mesylate
  last updated:	2008 Jul 9
  status:	recruiting
  sponsor:	Niguarda Hospital

   

• Imatinib in Dermatofibrosarcoma Protuberans (DFSP)

  conditions:	Dermatofibrosarcoma
  interventions:	Imatinib (Glivec)
  last updated:	2006 Sep 11
  status:	active, not recruiting
  sponsor:	Dermatologic Cooperative Oncology Group

   

• Imatinib in Systemic Sclerosis

  conditions:	Scleroderma, Systemic
  interventions:	Imatinib mesylate
  last updated:	2008 Jan 25
  status:	recruiting
  sponsor:	Stanford University

   

• Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients

  conditions:	Leukemia
  interventions:	Imatinib Mesylate
  last updated:	2009 May 21
  status:	completed
  sponsor:	M.D. Anderson Cancer Center